Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosfomycin intravenous - Nabriva Therapeutics

Next Previous
Drug Profile

Fosfomycin intravenous - Nabriva Therapeutics

Alternative Names: CONTEPO; Fosfomycin disodium; Fosfomycin for injection - Nabriva Therapeutics; IV fosfomycin - Nabriva Therapeutics; ZOLYD; ZTI-01

Latest Information Update: 15 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zavante Therapeutics
  • Developer Nabriva Therapeutics; National Institute of Allergy and Infectious Diseases; Zavante Therapeutics
  • Class Anti-infectives; Antibacterials; Epoxy compounds; Organophosphorus compounds; Phosphonic acids; Phosphoric acid esters; Small molecules
  • Mechanism of Action Cell wall inhibitors; Peptidoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Urinary tract infections
  • Phase II Intra-abdominal infections; Skin and soft tissue infections
  • No development reported Bacterial infections; Gram-negative infections; Nosocomial infections

Most Recent Events

  • 31 Dec 2022 Nabvira Therapeutics has patent protection for Fosfomycin intravenous in USA, prior to December 2022
  • 31 Dec 2022 Discontinued - Phase-I for Urinary tract infections (In children, In infants, In neonates, Complicated) in USA (IV), prior to December 2022
  • 22 Nov 2022 Chemical structure information added
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top